In order to investigate the safety and efficacy of kisspeptin-54 in women at high risk of developing OHSS, the inclusion criteria for this trial were a high serum AMH ≥40 pmol/L or AFC ≥23. The gene discussed is AMH; the disease is ovarian hyperstimulation syndrome.